Genpath Bioreference Laboratories Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail
IMAGE: Dr. O Dwyer is co-leading the largest precision medicine cancer clinical trial to date, NCI-MATCH, with 39 single-arm phase II treatment arms. Researchers are locating patients for the 12 remaining arms.
view more 
Credit: University of Pennsylvania
The NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) cancer clinical trial is expanding with the opening of a new treatment arm. The addition, Arm Z1M, is a single-arm phase II study of a two-drug combination, relatlimab and nivolumab, both immunotherapies. To be eligible, patients must have mismatch repair deficiency on genomic testing and tumors that express the
LAG-3 protein, a cancer immunotherapy target. The cancer must also have progressed on anti-PD-1/PD-L1 immunotherapy. The addition brings the number of available treatment arms in NCI-MATCH to 12. The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), part of the National Institutes of Healt ....

Puerto Rico , District Of Columbia , United States , Lyndsay Harris , Peterj Odwyer , National Cancer Institute , Group Co , Strata Oncology Inc , Omniseq Inc , Jackson Laboratory , Fashion Analytics , Division Of Cancer Treatment , Tempus Labs Inc , National Clinical Trials Network , National Institutes Of Health , Foundation Medicine Inc , Quest Diagnostics Inc , Neogenomics Laboratories Inc , Cancer Research Group , Genpath Bioreference Laboratories Inc , Caris Life Sciences , Cancer Diagnosis Program , Molecular Analysis , Therapy Choice , Research Group , National Institutes ,